Skip to main content
. 2023 Aug 22;14:1222267. doi: 10.3389/fimmu.2023.1222267

Figure 4.

Figure 4

Immunoreactivity profiles of BamA ECL4 mAbs. (A) Titration ELISAs of the mAbs against native and irrelevant peptides (magenta and grey, respectively) and PfTrxBamA/ECL4 and PfTrx Empty (blue and black, respectively). (B) mAb AUC values calculated for native peptide and PfTrxBamA/ECL4. (C) Immunoblot reactivities against graded nanogram amounts of PfTrx BamA/ECL4 (21.4 kDa) or the BamA β-barrel (44.9 kDa). Based on the MW, PfTrxBamA/ECL4 and BamA β-barrel were loaded at a 2:1 ratio, with 1 ng corresponding to 0.047 and 0.022 picomoles, respectively. PfTrxEmpty (200 ng) and nonspecific mAb (IGX6939) served as specificity controls. Immunoblots were done using mAbs at 4 μg/ml. (D) A rat polyclonal BamA ECL4 (residues 568–602) antiserum (10) (diluted 1:1,000) was used as a comparator. (E) Immunoblot reactivity of IGX7141 mAb (4 μg/ml) against graded nanogram amounts of Nichols (top) and Mexico A PfTrxBamA/ECL4 (bottom) variants.